Jefferies Raises PT and Estimates on Gilead Sciences (GILD); Stribild (Quad Pill) Approved

August 28, 2012 7:23 AM EDT Send to a Friend
Get Alerts GILD Hot Sheet
Price: $105.96 +0.03%

Rating Summary:
    22 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 21
Trade GILD Now!
Join SI Premium – FREE
Jefferies maintains a 'Hold' on Gilead Sciences (NASDAQ: GILD) price target of $55.00 (from $53.00).

Analyst, Thomas Wei, said, "The FDA approved GILD's Stribild (quad pill) with a label that was largely in line with expectations. GILD announced Stribild pricing of $28,500/year, which represents a premium to our assumption of $22,263. We are raising our PT to $55 on the basis of Stribild pricing, but we remain cautious on GILD based on valuation."

FY12 EPS estimate raised from $3.78 to $3.79 and FY13 from $4.05 to $4.12.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $57.19 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDA

Related Entities

Jefferies & Co

Add Your Comment